J G Coen van Hasselt
Overview
Explore the profile of J G Coen van Hasselt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van Os W, Nussbaumer-Proll A, Pham A, Wijnant G, Ngougni Pokem P, Van Bambeke F, et al.
J Antimicrob Chemother
. 2024 Jul;
79(10):2484-2492.
PMID: 39030832
Background: Temocillin is increasingly considered as an alternative to carbapenems. However, there is no consensus on optimal dosing strategies and limited data on temocillin efficacy in systemic infections. Objectives: We...
12.
Guo Y, Guo T, Knibbe C, Zwep L, van Hasselt J
J Pharmacokinet Pharmacodyn
. 2024 Jun;
51(6):735-746.
PMID: 38844624
Incorporating realistic sets of patient-associated covariates, i.e., virtual populations, in pharmacometric simulation workflows is essential to obtain realistic model predictions. Current covariate simulation strategies often omit or simplify dependency structures...
13.
Budda D, Gulave B, van Hasselt J, de Lange E
Br J Pharmacol
. 2024 Apr;
181(20):3856-3868.
PMID: 38663441
Background And Purpose: Morphine is important for treatment of acute and chronic pain. However, there is high interpatient variability and often inadequate pain relief and adverse effects. To better understand...
14.
Mehta K, Balazki P, van der Graaf P, Guo T, van Hasselt J
Clin Pharmacokinet
. 2024 Mar;
63(5):657-668.
PMID: 38530588
Background And Objective: The use of bedaquiline as a treatment option for drug-resistant tuberculosis meningitis (TBM) is of interest to address the increased prevalence of resistance to first-line antibiotics. To...
15.
van Os W, Pham A, Eberl S, Minichmayr I, van Hasselt J, Zeitlinger M
Int J Antimicrob Agents
. 2024 Mar;
63(5):107148.
PMID: 38508535
Objective: Predictions of antimicrobial effects typically rely on plasma-based pharmacokinetic-pharmacodynamic (PK-PD) targets, ignoring target-site concentrations and potential differences in tissue penetration between antibiotics. In this study, we applied PK-PD modelling...
16.
den Hartog I, Zwep L, Meulman J, Hankemeier T, van de Garde E, van Hasselt J
Metabolomics
. 2024 Mar;
20(2):35.
PMID: 38441696
Introduction: Longitudinal biomarkers in patients with community-acquired pneumonia (CAP) may help in monitoring of disease progression and treatment response. The metabolic host response could be a potential source of such...
17.
Tandar S, Aulin L, Leemkuil E, Liakopoulos A, van Hasselt J
J Pharmacokinet Pharmacodyn
. 2023 Nov;
51(3):199-211.
PMID: 38008877
The use of β-lactam (BL) and β-lactamase inhibitor (BLI) combinations, such as piperacillin-tazobactam (PIP-TAZ) is an effective strategy to combat infections by extended-spectrum β-lactamase-producing bacteria. However, in Gram-negative bacteria, resistance...
18.
Zwep L, Guo T, Nagler T, Knibbe C, Meulman J, van Hasselt J
Clin Pharmacol Ther
. 2023 Nov;
115(4):795-804.
PMID: 37946529
Virtual patient simulation is increasingly performed to support model-based optimization of clinical trial designs or individualized dosing strategies. Quantitative pharmacological models typically incorporate individual-level patient characteristics, or covariates, which enable...
19.
Mehta K, Guo T, van der Graaf P, van Hasselt J
Br J Clin Pharmacol
. 2023 Oct;
90(2):463-474.
PMID: 37817504
Aims: Bedaquiline, pretomanid and linezolid (BPaL) combination treatment against Mycobacterium tuberculosis is promising, yet safety and adherence concerns exist that motivate exploration of alternative dosing regimens. We developed a mechanistic...
20.
Liu F, Aulin L, Manson M, Krekels E, van Hasselt J
Eur J Drug Metab Pharmacokinet
. 2023 Sep;
48(6):623-631.
PMID: 37715056
Methods: A physiologically based model incorporating renal and hepatic drug clearance was implemented. Functions correlating IL-6 levels with GFR and in vitro CYP3A4 activity were derived and incorporated into the...